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lems with the EQ-5D. This is due to the original scoring methods used
and how negative time trade-off (TTO) values were treated. A revised
scoring method has been published. This article applies this to an in-
flammatory arthritis cohort. The objective is to examine the impact of
a revised scoring system for the EQ-5D (UK) TTOon the utility estimates
and in the case of rheumatoid arthritis, to explore the impact of using
different utility metrics on the incremental cost-effectiveness ratio
(ICER) results of an economic model. Methods: A total of 504 patients
ith inflammatory arthritiswere rescored using revised EQ-5D scoring,
hich uses an episodic randomutilitymodel to deal with negative TTO
alues. Differences in utility scores were compared and the new map-
ing coefficients were obtained. These were then used in an economic
odel to examine the impact on the ICER. Results: In rheumatoid ar-
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doi:10.1016/j.jval.2011.03.002thritis, the overall change is less for the revised EQ-5D scoring than
with the original EQ-5D (TTO) but greater than the SF-6D: EQ-5D UK
0.22 (95% confidence interval [CI] 0.30 to 0.15), revised EQ-5D UK
0.16 (95% CI 0.21 to 0.10) and SF-6D 0.08 (95% CI 0.11 to 0.05).
A similar trend is seen in the psoriatic arthritis group. The economic
model produced different ICERs, when different utility measures were
used; EQ-5D (TTO) €42,402, SF-6D €111,788, and revised EQ-5D (TTO)
€57,747. Conclusion: In the context of inflammatory arthritis, this ar-
ticle demonstrates that a revised scoring for EQ-5D may have a signif-
icant impact on utility estimates and on the output of the economic
model.
Keywords: EQ-5D, scoring, SF-6D, utility.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are part of
a group of conditions described as inflammatory arthritis. They
are chronic, progressive conditions that place a substantial bur-
den on patients, their caregivers, and the health service. The
most common of these conditions are RA and PsA. RA, in par-
ticular, has a negative effect on quality of life (QOL), including
physical, psychological, and social functioning, and is associ-
ated with premature mortality [1]. PsA presentation ranges
from mild impairment of function that can be adequately
treated with mild therapeutic interventions to severe disease
with erosive arthropathy that may result in significant func-
tional disability and increased mortality [2].
Measurement of patients’ response to treatment via QOL in-
struments is now one of the recommendedmethods for quantify-
ing the effectiveness of a technology in economic evaluations
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Published by Elsevier Inc.around the world [3–6]. QOL is quantified using a single index
figure anchored between 0 and 1, with 0 indicating immediate
“death” and 1 indicating “perfect health.” This figure has been
termed a utility value. QOL can be measured using direct and indi-
rect methods. Direct measurement asks a person to value directly
his or her own health or a relevant disease-specific state using a
valuation task such as time trade-off (TTO) or standard gamble
(SG). Indirect measurement involves QOL questionnaires, for ex-
ample, EQ-5D or SF-6D, in which the patient completes questions
on his or her current health state, and these responses are scored
using weights or preferences obtained from the general popula-
tion. There are documented differences in the utility values pro-
duced in these ways with indirect methods giving consistently
lower levels of utility than direct methods [7]. Indirect generic
measures such as the EQ-5D [8] and the SF-6D [9] are the most
commonly used, and a single index measurement of QOL can be
derived.
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922 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 2 1 – 9 2 7A variety of instruments have been used to measure both dis-
ease severity in RA and PsA and the impact of this severity onQOL,
particularly in inflammatory arthritis trials [10–13]. These mea-
sures include clinical instruments that measure disease activity,
such as the European League Against Arthritis disease activity
score (DAS) [14], disease-specific instruments such as the Health
Assessment Questionnaire (HAQ) [15], and generic instruments
such as the EQ-5D [8] and SF-36 [16].
All instruments display some shortcomings in assessing
ealth-related QOL (HR-QOL) in inflammatory arthritis [17,18]. Al-
though using generic measures should theoretically allow us to
compare results for a variety of conditions, disparities have been
shown to exist in the utilities derived from the EQ-5D and SF-6D,
and this is attributed to the different descriptive systems, the val-
uations attached to the health states, or a combination of these
[19]. This has important implications for economic analyses of
treatments such as biological therapy in inflammatory arthritis,
which is more likely to be used for patients in severe health states
than those inmild health states. If we cannotmeasure the change
in these categories accurately, the full potential of the treatment
may not be adequately measured.
It is well established that the EQ-5D and the SF-6D produce
different utility values in the same cohort [20,21]. This is in part
due to different definitions of perfect health. According to the 1995
Health Survey of England, the EQ-5D considers more than half of
the population to be in perfect health, whereas the SF-6D consid-
ers less than 3% to be in perfect health [22].
Therefore, the SF-6D has a different criterion for perfect health
than the EQ-5D. This presents decisionmakers with a challenge in
comparing results of economic evaluations that have used differ-
ent methods to calculate utility. In an RA cohort, the utility gain
produced by the EQ-5D is twice that produced by the SF-6D [20,23].
This discrepancy between the measures has been the subject of a
number of recent publications that highlight [20,24–28] the meth-
odology of the original scoring of the EQ-5D (UK) and the manner
in which worse-than-dead (WTD) values were adjusted [29]. Using
an inflammatory arthritis cohort, a recent study found that the
floor utility value measured by the EQ-5D was 0.43 and that 17%
of utility values in this cohort were WTD. The prevalence of neg-
ative values had a profound effect on the burden of disease esti-
mates in this article [20]. The lowest measured value in the group
for SF-6D was 0.29.
In an attempt to lessen the heterogeneity between these two
measures, we used a revised scoring method for the EQ-5D and
rescored a rheumatology cohort receiving biological therapy [26].
We compared the scores to the utility values produced by the orig-
inal scoringmethods for both RA and PsA. We then used themap-
ping coefficients calculated for RA in a RA model and compared
the incremental cost-effectiveness ratio (ICER) results using differ-
ent measures. The aim of our analysis is to examine the impact of
a revised scoring systemon the utility estimates and, in the case of
RA, on the results of an economic model.
Methods
Data source
Utility data were derived from a database of 504 patients from a
tertiary referral center in the Irish health-care setting that records
the clinical and QOL outcomes of patients receiving biological
therapy for RA and PsA. Patients included in this study have a
diagnosis of either RA according to the American College of Rheu-
matology criteria or PsA according to CASPAR (ClASsification cri-
teria for Psoriatic Arthritis) criteria and commenced biological
therapy (anti–tumor necrosis factor- monoclonal antibodies, B-
cell antagonists, or T-cell modulators). aInstruments used
TheQOL instruments usedwere the paper versions of the EQ-5D (3
level), SF-36 (version 1), and the modified HAQ. The EQ-5D, SF-36,
and HAQ were collected as part of normal clinical practice for
monitoring the impact of treatment on QOL. All questionnaires
were measured at baseline before the start of therapy and at fol-
low-up at 12 months.
The Disease Activity Score 28 (DAS28) was collected as one of
the clinical outcomes in monitoring response to treatment and
disease activity [14]. This instrument incorporates the number of
both swollen and tender joints, a laboratory measure of inflam-
mation such as the erythrocyte sedimentation rate and C-reactive
protein (CRP), and a patient-assessed global disease impact mea-
sure. The DAS28 first developed for RA incorporates just 28 of the
68 joints. The DAS28 is an index that can assess disease activity
and also be used to derive a response measure [30].
The HAQ is the physical disability scale (Modified HAQ) that
measures function in relation to the degree of difficulty experi-
enced in performing activities of daily living such as dressing, ris-
ing, personal hygiene, walking, eating, and the ability to carry out
chores. The HAQ contains 20 items across 8 domains that are
scored from 0 (no difficulty) to 3 (unable to do) [15]. The HAQ Dis-
ability Index (HAQ-DI) is the single index score derived from scor-
ing the HAQ.
The SF-6D is derived from the SF-36 and uses 11 items from the
36 items of the RAND Medical Outcomes Study short-form health
survey (SF-36) [9,16]. Scoring data for the SF-6D were collected
using the SG valuation technique on a random sample (n 836) of
the general population in the United Kingdom [9]. The SF-6D scor-
ing algorithm was revised in 2007 using nonparametric bayesian
analysis [31]. The bayesian version overcomes some of the bias of
the original regressionmodels when assigning values to the worst
health states (e.g., it yields a value of 0.203 for the worst SF-6D
state compared to 0.301 using the original parametric algorithm).
The bayesian estimates of the SF-6D utilities were calculated in
Microsoft Excel (further details of the methodology are available
from the University of Sheffield) [32].
Methods used to calculate utilities
The EQ-5D index is a preference-based indexmeasure inwhich an
individual provides an assessment of each component of his/her
health status according to a structured health-status classification
system, and a single preference-based score is derived for each
individual based on societal preferences [29]. It is used extensively
to measure QOL in inflammatory arthritis [33–35] The EQ-5D has
five dimensions, eachwith three levels of severity (level 1, no prob-
lems to level 3, extreme problems). Therefore, the instrument can
produce 243 health states, 35. An additional two health states are
included: “dead” and “unconscious.”
Scoring method for the UK TTO
The preferences for the scoring function weremeasured using the
TTO technique on a random sample of 2997 adults of the UK pop-
ulation (Measurement of Health [MVH] study) [29]. Dolan [29] de-
ised a scoring method that assigned a single index utility value
or each health state described. Forty-five of the health stateswere
cored directly from the population using TTO valuation, and the
alues of the remaining states were predicted using regression
stimates.
To anchor the scale, perfect health and dead were assigned
cores of 1 and 0, respectively. For states described as better than
ead (BTD) (0) on the TTO, scores were calculated using the for-
ula x/10, where x is the number of years spent in perfect health
equal to 10 years in the health state. For states scored asWTD (0),
the formula given is x/(10 x), where immediate death equates to
scenario of x years in perfect health followed by (10 x) years in
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923V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 2 1 – 9 2 7the health state. For states BTD, the ratios range from 1 to 0, but
ratios for WTD states lie between 0 and 39 (the WTD x has an
upper bound at 9.75 years). The asymmetry seen between the pos-
itive and negative ratios seem to inflate the influence of the WTD
responses; therefore, Dolan transformed the negative ratios to
x/10, replacing 34% of the TTO responses [36]. By bounding the
negative ratio at 1, the influence of these WTD responses on the
mean slope lessened and improved face validity of mean ratio
estimates.
Revised scoring method for the EQ-5D UK
To provide an alternative method for handling the challenges
posed in valuing the WTD states in the MVH study, Craig and
Busschbach [26] re-examined the original data using an episodic
regression model instead of a ratio regression model. The health
state valuations have been published, and these are provided in
Appendix 1 in found at doi:10.1016/j.val.2011.03.002 [37]. The the-
oretical basis for both models was presented in a previously pub-
lished paper [38]. The utility of a health state j over time t for an
ndividual i is random and can be represented by:
ijt  jt  ij Episodic RUMj  ij t  jt  ijt Instant RUM
he main distinguishing factor between these models is how the
TD TTO responses are interpreted, and this differs greatly be-
ween the episodic and the instant. In the episodic random utility
odel (RUM), the error represents variability in the value of an
pisode (error associated with time). In the instant RUM, the error
epresents variability of an instantaneous state, not the episode,
nd suggests a random slope with respect to time. The regression
odel of the episodic RUM treats the time in perfect health as the
ependent variable and the time in the health state as the inde-
endent variable. The coefficient is the value estimator, not a
ean ratio. The central advantage of the episodic RUM over the
Table 1 – Baseline demographics.
Characteristic RA (n  345), m
Female sex, no. (%) 2
Age at inclusion in years 54  12.
Duration of disease in years 12  9.4
ESR 35  25.
CRP 29  29.
DAS28: C-reactive protein 5.39  1.1
Patient Global Assessment (10 cm VAS) 6  2.3
Pain (10 cm VAS) 6  2.3
Tender joint count (range 0–28) 5  2.3
Fatigue (10 cm VAS) 6  2.4
Swollen joint count (range 0–28) 10  6.6
Tender joint count (range 0–66) 10  6.0
Concomitant methotrexate, (n, %) 2
Previous DMARDs, (n)
HAQ-DI (0–3) 1.3  0.7
SF-36 PCS (0–100) 30  8.5
SF-36 MCS (0–100) 45  10.
SF-6D utility 0.54  0.0
EQ-5D UK TTO utility 0.43  0.3
Revised EQ-5D UK TTO utility 0.576  0.2
CRP, C-reactive protein; DAS28, Disease Activity Score (28 joint); DMA
tation rate; HAQ, Health Assessment Questionnaire; HAQ-DI, Health
mary; PCS, physical component summary; PsA, psoriatic arthritis; RA
* Unless otherwise indicated.
† Missing data (n  18 patients).
‡ Missing data (n  4).riginal approach is that this procedure does not involve arbitrary
ransformations of the WTD responses.
Statistical analysis
Descriptive statisticswere used to describe the baseline demograph-
ics;mean values, range, and SD are given. A paired-sample t testwas
used tocompare themeanutilityatbaselineandat follow-upandthe
mean change measured by the original EQ-5D UK TTO, the revised
EQ-5D UK, and the SF-6D. Confidence intervals (CIs) (95%) are pre-
sented around the change in utility and the ICER estimates. Statisti-
cal analysis was performed using Statistical Package for Social Sci-
ences (SPSS) Version 16 (SPSS Inc., Chicago, IL).
Statistical models used
General linear models were fitted for each of the measures with
HAQ-DI and DAS28. Quadratic and higher dimensional models
were examined but did not have a statistically significantly im-
provedfit than the linearmodel. For each of the regressionmodels,
standard errors, 95% CIs and R2 are shown.
ICER calculation
To calculate an ICER for the RA group, we used the mapped coeffi-
cients of the threedependent variables (original EQ-5D (TTO), revised
EQ-5D (TTO), and theSF-6D) topopulateanRAmodel.Themodelwas
run separately for each of the three methods. In the RA model, dis-
ease changes are driven by changes to patients’ HAQ-DI scores, and
therefore it was the HAQ-DI and utility coefficients that were used.
Themodel incorporates a linear equation tomodel the utility change
as mapped from the HAQ-DI. Although newer models now use a
quadratic equation to describe the relationship between utility and
HAQ-DI, in this case, there was no significant statistical difference
between the quadratic model and the linear model [39]. The model
 SD (range)* PsA (n  159), mean  SD (range)*
) 82 (52)
85) 45  12.8 (15, 77)
) 11  10.1 (0, 45)
40) 22  21.1 (1, 120)
58) 18  22.7 (0, 149)
) 4.91  1.0 (1, 7)
) 5.5  2.3 (0, 10)
) 5  2.3 (0, 10)
) 8  6 (0, 28)
) 6  2.6 (0, 10)
) 7  6 (0, 28)
) 12  9 (0, 43)
) 56 (35)
118‡
0.96  0.7 (0, 2.5)
7) 34  9.5 (13, 58)
72) 46  12.2 (20, 66)
, 0.7) 0.57  0.12 (0.25, 0.80)
.43, 1) 0.53  0.32 (0.24, 1)
.14, 0.9954) 0.638  0.19 (0.046, 0.9954)
disease-modifying antirheumatic drugs; ESR, erythrocyte sedimen-
sment Questionnaire Disease Index; MCS, mental component sum-
umatoid arthritis; VAS, visual analogue scale.ean
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924 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 2 1 – 9 2 7was populated using Irish cost data. Our objective was to examine
the change in the ICER when the utility estimates are changed.
Results
Patient demographics
At baseline, the mean age at inclusion was 54 years for the RA
cohort and 45 years for the PsA group (Table 1). The average dis-
ease duration was similar (RA  12 years, PsA  11 years). The
mean DAS28 was significantly higher in the RA group (5.39 [95% CI
5.16–5.43]) than in the PsA group (4.91 [95% CI 4.65–5.05]), as was
the mean HAQ-DI (RA: 1.3 [95% CI 1.26–1.46] vs. PsA: 0.96 [95% CI
0.81–1.08]).
The mean utility scores and SDs are provided for each of the
three methods (Table 2). In the RA group, the overall change was
less for the revised EQ-5D scoring than the original EQ-5D (TTO)
but greater than the SF-6D (Table 2). The changewas greater in the
PsA group across all threemethods, and a trend between the scor-
ing methods was seen similar to that in the RA group; the greatest
change was produced when using the EQ-5D, less so with the re-
vised method, and considerably less so with the SF-6D.
To describe the relationship between the measures, we fitted
regression lines between each of the QOL instruments and the
HAQ-DI and DAS28. The equations for the mapping, including the
coefficients of the regression, are presented in Appendix 2 found
at doi:10.1016/j.val.2011.03.002. We calculated both a linear equa-
tion and a quadratic equation for each of the methods and HAQ-
DI. Because there was no statistical difference between the mod-
els, we used the more parsimonious linear model. We plotted the
regression lines for the measures to investigate the relationship
between them (Fig. 1).
The revised scoring for the EQ-5D lessens the gap between the
SF-6D and the original EQ-5D (Fig. 1). The slope produced by the
relationship between the HAQ-DI and the revised scoring is less
steep than that produced by the HAQ-DI with the original scoring.
The distribution of the utility score produced by the twometh-
Fig. 1 – Comparison of the fitted lines associating mapped
utility from the revised EQ-5D UK scoring, original EQ-5D
UK, and the SF-6D with the Health Assessment
Questionnaire (HAQ) Disability Index score.ods of scoring for the EQ-5D differs. The marginal distribution of
T S E R
h925V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 2 1 – 9 2 7each of these measures is provided in Figure 2. The distribution of
the scores was narrower with the revised scoring system (range
0.143 to 0.995) than the original EQ-5D scoring method (range
0.429 to 1.0) in this cohort.
We plotted the results of both measures on a scatterplot. The
line is the line of equality. The methods produce different results
to the original method for utility scores less than 0.5. The magni-
tude of this difference is approximately 0.25 for scores less than 0.5
(Fig. 3).
Impact on ICER
The ICER for a biological agent is presented for each of the utility
measures. The original EQ-5Dmapping produced the lowest ICER,
€42,402 (95%CI €36,837–€52,061). The SF-6Dmapping produced the
ighest ICER, €111,788, and lies outside the acceptable willingness
to pay range for most decisionmakers. The 95% CI was €105,154 to
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Fig. 2 – Histograms of the EQ-5D and revised EQ-5D
showing the marginal distribution for each of these
measures for this cohort. Of note in the revised version is
the impact on individuals with values less than 0.€141,665. The EQ-5D mapping using the revised scoring methodfell between these twomeasures, €57,747, with a 95% CI of €52,032
to €72,845.
Discussion
There is a substantial burden of evidence highlighting the prob-
lems associated with the EQ-5D; this evidence is primarily refer-
ring not to the instrument itself but to the preference-based scor-
ingmethod thatwas used to assign population-weighted values to
the raw TTO scores [28,39]. The area of most concern with the
original scoring method is how the WTD states were handled.
Recent articles propose an alternative method to handle WTD
states, but, to date it has not been demonstrated how this method
could in practice alter the utility estimates and ultimately the re-
sults of an economic model [26,36].
In this article, we present the utility estimates from a large
cohort of rheumatology patients scored using this alternative
scoring method for the EQ-5D (TTO). In doing so, we provide a
practical application of this revised method in an observational
cohort of patients and demonstrate that the mean utility esti-
mates produced by each of these methods differ considerably,
which in turn influence the estimates of the economic model
(Table 2).
The revised method used here handles the raw scores differ-
ently, and as a result, the distribution of scores observed when
using the revised EQ-5D scoringmethod is narrower than the orig-
inal method [26]. The lowest score in this cohort with the revised
method is 0.143 and with the original method is 0.43.
The range of ICERs estimated using three different methods
of utility measurement highlights the impact that utility has on
the overall result in the case presented here. Although a prag-
matic approach may be to recommend that one utility measure
(either directly measured using questionnaires or via mapping)
is used for all economic evaluations, this may restrict our ability
to explore uncertainty associated with this parameter. Probabi-
listic sensitivity analysis explores uncertainty within the limits
of the instrument measured. To examine the heterogeneity be-
tween utility measures, it may be useful to refit a cost-effective-
ness model using multiple metrics and produce a range of ICER
estimates.
Fig. 3 – Scatterplot of utilities derived from the revised EQ-
5D scoring and original EQ-5D scoring. A line of equality is
fitted.
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926 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 2 1 – 9 2 7This article also compares the utility estimates of the SF-6D to
those of the EQ-5D using both scoring methods. One of the main
areas of concern for economic evaluations is the lack of concor-
dance between the twomain generic QOL instruments: the EQ-5D
and the SF-6D. Although there are well-documented reasons for
this, the problem remains that they produce quite different results
in QALY estimation [24,40–42]. It is unlikely that these instru-
ments will ever produce a similar result because of their differing
descriptive systems. According to the Health Survey of England,
perfect health is largely absent from the SF-6D system and preva-
lent in the EQ-5D system [43]. A reasonable assumption is that the
true estimatemay lie somewhere between bothmeasures.We can
see that the revised scoring produces an estimate that lies be-
tween the slope of the original EQ-5D and the SF-6D (Fig. 1) and
produces a change that that is less than the original EQ-5D and
more than the SF-6D (Table 2). The SF-6D valuation study exam-
ined SG responses without WTD responses, except for one state
(i.e., pits). The worse imaginable health state, “pits” was valued in
amanner similar to that for the valuations in theDolan article [29].
In future research, it would be prudent to rescore the SF-6D values
and compare the difference in results overall.
This alternative scoring method is useful in corroborating
some of the reasons for the discrepancies in the scoring of the
EQ-5D that have been presented by other authors [26,44]. Dolan
[29] replaced the negative slopes with x/10, whereas Shaw et al.
[45]. (US valuation) divided the negative slopes by a constant (i.e.,
39). The episodic RUM reduces dependence on these arbitrary ad-
justments that have been made to deal with WTD valuations and
provides a more robust coefficient estimator.
It is noted that the proportion of states consideredWTD by the
original UK EQ-5D values ismuch higher in this population than in
others [44] (17% WTD at baseline in the Irish cohort). The impact
on the ICER is significant, and it would be of benefit to establish
whether such change would be seen in other less severe disease
states. Although the methodology for this rescoring is relatively
new, the revised results are more concordant with the SF-6D pre-
dictions, suggesting convergent validity. Althoughwe can see how
the approach changes the results in this cohort, it would be of
interest to examine the effect across a number of different geo-
graphic populations and for different diseases.
Conclusion and recommendations
This article presents the results from a large cohort, using an al-
ternative method for scoring the EQ-5D, and examines the rela-
tionship between both the revised and original generic measures
(EQ-5D and SF-6D) and disease measures (HAQ-DI and DAS28) in
inflammatory arthritis.
In the context of inflammatory arthritis, this article demon-
strates that choice of scoring method of TTO utility measure may
have a significant effect on the ICER, whichmay therefore have an
impact on the reimbursement decision. Furthermore, in choosing
just one QOL measure to produce a single ICER estimate, we may
be restricting our ability to fully explore the uncertaintywithin the
final estimate of a cost-effectiveness analysis.
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